PLURI
LIVE

Serial Number

79420419

Owner

PLURI BIOTECH LTD

Filing Date

Dec 1, 2024

Add to watchlist:

No watchlists yet
View on USPTO

PLURI Trademark

Serial Number: 79420419

PLURI is a trademark filed by PLURI BIOTECH LTD on December 1, 2024. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently pending registration.

Owner Contact Info

PLURI BIOTECH LTD (4 trademarks)

Matam 20

Entity Type: 99

Trademark Details

Filing Date

December 1, 2024

Registration Date

Not Registered

Goods & Services

Scientific and technological services and research and relating to isolation and culturing of animal cells and plant cells and to animal and plant tissues isolation and culturing, to biological preparations intended for medical, clinical, and scientific use of cultured cells and their extracts, to bioengineered cells and/or tissues, to bioengineered cells for use in immunotherapy for cancer and other diseases, to bioengineered human T cells, to isolated and cultivated human and animal placentas cells, to isolated plant cells and their extracts, to isolated and cultivated adherent cells from placenta tissue, to isolated and cultivated adherent stromal cells derived from placentas of multiple donors, to isolated and cultivated mammal cells, their extracts and preparations containing them, to isolated and cultivated fish cells and/or sea food cells and preparations containing the same, to isolated and cultivated plant cells and their extracts and preparations containing the same, to research, development and testing services in the fields of mass production of animal and plant cells, to research, development and testing services in the fields of large scale production of various cells in bioreactors.

Biological preparations for use in industry and science; bioengineered cells for use in industry and science; bioengineered human T cells for use in industry and science; human and animal cells from placentas for use in industry and science; human and animal cells from placentas for use in the manufacture of cosmetic and aesthetic products; human and animal cells from placentas for use in biological preparations for prevention of hair loss; isolated plant cells, their extracts, and components for use in industry and science; isolated and cultivated adherent cells from placenta tissue for use industry and science; isolated and cultivated adherent stromal cells derived from placentas of multiple donors for use in industry and science; isolated and cultivated mammal cells, their extracts and components for use in industrial manufacture of foodstuff; isolated and cultivated fish cells and/or sea food animal cells for use in industrial manufacture of foodstuff; isolated and cultivated plant cells and their extracts for use in industrial manufacture of foodstuff.

Cells and biological preparations intended for medical and clinical use; bioengineered cells and/or bioengineered tissue for medical and clinical use; bioengineered cells for use in immunotherapies for cancer and other diseases; bioengineered human T cells for medical and clinical use; human and animal cells from placentas for medical and clinical use; dietary supplements based on human and animal cells from placentas for cosmetic and aesthetic use; dietary supplements and medical preparations based on human and animal cells from placentas for use in prevention of hair loss; isolated plant cells, their extracts and components for medical and clinical use; isolated and cultivated adherent cells from placenta tissue for medical and clinical use; isolated and cultivated adherent stromal cells derived from placentas of multiple donors for medical and clinical use; isolated and cultivated mammal cells and their extracts for medical and clinical use and preparations containing the same; isolated and cultivated fish cells and/or sea food animal cells for medical and clinical use and preparations containing the same; isolated and cultivated plant cells, their extracts and components for medical and clinical use and preparations containing the same.

Filing History

REFUSAL PROCESSED BY IB
Mar 12, 2026 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 20, 2026 RFCS
REFUSAL PROCESSED BY MPU
Feb 20, 2026 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 27, 2026 RFCR
NON-FINAL ACTION WRITTEN
Jan 26, 2026 CNRT
ASSIGNED TO EXAMINER
Jan 24, 2026 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 23, 2026 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 23, 2026 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Apr 3, 2025 REPR